The China NMPA Approves TYVYT® + Bevacizumab + Chemotherapy in Patients with EGFR-mutated nsqNSCLC who Progressed after EGFR-TKI Therapy May 18, 2023
Updated Results from ORIENT-31 Study of Sintilimab + Chemo +/- Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated nsqNSCLC announced May 10, 2023
Imfinzi-based treatment before & after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable NSCLC in the AEGEAN Ph 3 trial April 20, 2023
Positive topline data announced from Part A safety lead-in of THIO-101 Ph 2 trial in advanced NSCLC April 20, 2023
Scorpion Therapeutics and Pierre Fabre to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFRm NSCLC April 12, 2023
First Subject Dosed in Ph 1 KisMET-01 Clinical Trial of MYTX-011 for the Treatment of NSCLC April 12, 2023
FDA Accepts Supplemental NDAs for BRAFTOVI + MEKTOVI in patients with mNSCLC with a BRAF V600E mutation April 12, 2023
First Patient Dosed in the Ph 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced NSCLC April 6, 2023
Neoadjuvant Opdivo + chemo Demonstrate Long-Term, Durable Clinical Benefits in Resectable NSCLC at 3 Years in the CheckMate -816 Trial April 6, 2023
New RYBREVANT (amivantamab-vmjw) Data Showed Long-Term Clinical Response and Safety in Patients with Advanced NSCLC with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy April 6, 2023
Updated Efficacy and Safety of Taletrectinib in Patients with ROS1-Positive NSCLC announced April 6, 2023
Open-Label Arm of Ph 2 KeyVibe-002 Trial of MK-7684A (Coformulation of Vibostolimab and Keytruda) to continue in Previously Treated mNSCLC Patients March 31, 2023
FAILED TRIAL: Ph 2 KeyVibe-002 Trial of MK-7684A (Vibostolimab + Pembrolizumab) in Previously Treated NSCLC patients did not meet primary PFS endpoint March 31, 2023
Ph 3 KEYNOTE-671 Trial Met Primary Endpoint of EFS in Patients With Resectable Stage II, IIIA or IIIB NSCLC March 15, 2023
Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Mets from NSCLC March 15, 2023
Tagrisso demonstrated strong OS benefit in the ADAURA Ph 3 trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer March 15, 2023
Imfinzi significantly improved EFS in AEGEAN Ph 3 trial for patients with resectable NSCLC March 15, 2023
Libtayo® (Cemiplimab) + Chemotherapy combo Receives Positive CHMP Opinion For The Treatment Of Advanced PD-L1 Positive NSCLC March 15, 2023
Imfinzi plus Imjudo approved in the EU for patients with 1L HCC and mNSCLC based on significant survival benefits in HIMALAYA and POSEIDON Ph 3 trials February 28, 2023
Wellmarker Bio Announces Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA February 22, 2023
